Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity in glioblastoma

Journal of Neuro-Oncology

Volumn 128, Issue 2, 2016, Pages 333-339

  Brigliadori, Giovanni ^a   Foca, Flavia ^a   Dall’Agata, Monia ^a   Rengucci, Claudia ^a   Melegari, Elisabetta ^a   Cerasoli, Serenella ^b   Amadori, Dino ^a   Calistri, Daniele ^a   Faedi, Marina ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b BUFALINI HOSPITAL   (Italy)

Author keywords

Glioblastoma; MGMT promoter methylation percentage; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLASSIFICATION; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROMOTER REGION; PYROSEQUENCING; REFERENCE VALUE; SURVIVAL TIME; TREATMENT RESPONSE; AGE; BRAIN TUMOR; DNA METHYLATION; FOLLOW UP; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL ANALYSIS; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84962280602     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-016-2116-y     Document Type: Article

References (26)

1. McGirt MJ, Than KD, Weingart JD et al (2009) Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg 110:583–588. doi:10.3171/2008.5.17557
2. Brennan CW, Verhaak RGW, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477. doi:10.1016/j.cell.2013.09.034
3. Moskowitz SI, Jin T, Prayson RA (2006) Role of MIB1 in predicting survival in patients with glioblastomas. J Neurooncol 76:193–200
4. Shinojima N, Kochi M, Hamada J et al (2004) The influence of sex and the presence of giant cells on postoperative long-term survival in adult patients with supratentorial glioblastoma multiforme. J Neurosurg 101:219–226
5. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018
6. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
7. Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery. 62:753–766. doi:10.1227/01.neu.0000318159.21731.cf
8. Sanai N, Polley MY, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg 115:3–8. doi:10.3171/2011.2.JNS10998
9. Stummer W, Pichlmeier U, Meinel T et al (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomized controlled multicentre phase III trial. Lancet Oncol 7:392–401
10. Stupp R, Mason WP, Van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
11. Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
12. Shah N, Lin B, Sibenaller Z et al (2011) Comprehensive analysis of MGMT promoter methylation: correlation with MGMT expression and clinical response in GBM. PLoS One 6:e16146. doi:10.1371/journal.pone.0016146
13. Reifenberger G, Hentschel B, Felsberg J et al (2012) Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Int J Cancer 131:1342–1350. doi:10.1002/ijc.27385
14. Lattanzio L, Borgognone M, Mocellini C et al (2014) MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens. Int J Biol Markers 30(2):e208–e216
15. Håvik AB, Brandal P, Honne H et al (2012) MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. J Transl Med 10:36
16. Preusser M, Berghoff AS, Manzl C et al (2014) Clinical neuropathology practice news 1–2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma. Clin Neuropathol 33:6–14
17. Quillien V, Lavenu A, Sanson M et al (2014) Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol 116:487–496. doi:10.1007/s11060-013-1332-y
18. Wick W, Weller M, Van den Bent M et al (2014) MGMT testing—the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10:372–385. doi:10.1038/nrneurol.2014.100
19. Dunn J, Baborie A, Alam F et al (2009) Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 101:124–131. doi:10.1038/sj.bjc.6605127
20. Malley DS, Hamoudi RA, Kocialkowski S et al (2011) A distinct region of the MGMT CpG island critical for transcriptional regulation is preferentially methylated in glioblastoma cells and xenografts. Acta Neuropathol 121:651–661. doi:10.1007/s00401-011-0803-5
21. Wen YP, Macdonald RD, Reardon AD et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro oncology working group. J Clin Oncol 28:1963–1972
22. Xie H, Tubbs R, Yang B (2015) Detection of MGMT promoter methylation in glioblastoma using pyrosequencing. Int J Clin Exp Pathol 8:636–642
23. Quillien V, Lavenu A, Karayan-Tapon L et al (2012) Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA methyltranferase in a series of 100 glioblastoma patients. Cancer 118:4201–4211. doi:10.1002/cncr.27392
24. Lai K, Chen Y, Guan X et al (2014) Genome-wide methylation analyses in glioblastoma multiforme. PLoS One 9:e89376. doi:10.1371/journal.pone.0089376
25. van Vlodrop IJ, Niessen HEC, Derks S et al (2011) Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 17:4225–4231. doi:10.1158/1078-0432.CCR-10-3394
26. Bady P, Sciuscio D, Diserens AC et al (2012) MGMT methylation analysis of glioblastoma on the infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560. doi:10.1007/s00401-012-1016-2